Article: Z-ligustilide potentiates the cytotoxicity of dopamine in rat dopaminergic PC12 cells

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleZ-ligustilide potentiates the cytotoxicity of dopamine in rat dopaminergic PC12 cells
AuthorsQi, H1
Zhao, J1
Han, Y2
Lau, ASY1
Rong, J1
KeywordsCytotoxicity
Dopamine
Parkinson's disease
Reactive oxygen species
Reduced glutathione
Issue Date2012
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springerlink.com/content/1029-8428
CitationNeurotoxicity Research, 2012, v. 22 n. 4, p. 345-354 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12640-012-9319-6
AbstractDopamine toxicity is an ongoing controversy surrounding the use of levadopa (L-Dopa) in the therapy of Parkinson's disease. The initial objective of this study was to investigate the potential of neuroprotective botanicals such as Z-ligustilide in reducing the cytotoxicity of dopamine. We surprisingly found that Z-ligustilide potentiated dopamine toxicity in a dopaminergic cell specific manner. Using rat dopaminergic cell line PC12 as a model, we demonstrated that dopamine and Z-ligustilide in combination profoundly induced cell death, although these drugs alone, to a lesser extent, affected the cell viability in a concentration-dependent manner. The synergistic cytotoxicity of dopamine and Z-ligustilide is likely mediated via apoptosis, characterized by DNA fragmentation and chromatin shrinking after 12 h incubation. By measuring the intracellular reactive oxygen species (ROS) and reduced glutathione (GSH), Z-ligustilide and dopamine in combination dramatically enhanced the ROS formation and further depleted reduced GSH, whereas these drugs alone showed much less activity. Importantly, the synergistic cytotoxicity of dopamine and Z-ligustilide could be largely prevented by thiol-containing antioxidant N-acetylcysteine and GSH other than vitamin C and Trolox. Since the cytotoxicity of Z-ligustilide was not reported previously, the results of this study should raise public concerns over the potential risk associated with the combined use of herbal medicines containing Z-ligustilide with L-Dopa in the therapy of Parkinson's disease.
ISSN1029-8428
2011 Impact Factor: 3.514
2011 SCImago Journal Rankings: 0.230
DOIhttp://dx.doi.org/10.1007/s12640-012-9319-6
DC Field
Value
dc.contributor.authorQi, H
dc.contributor.authorZhao, J
dc.contributor.authorHan, Y
dc.contributor.authorLau, ASY
dc.contributor.authorRong, J
dc.date.accessioned2012-07-16T09:48:41Z
dc.date.available2012-07-16T09:48:41Z
dc.date.issued2012
dc.description.abstractDopamine toxicity is an ongoing controversy surrounding the use of levadopa (L-Dopa) in the therapy of Parkinson's disease. The initial objective of this study was to investigate the potential of neuroprotective botanicals such as Z-ligustilide in reducing the cytotoxicity of dopamine. We surprisingly found that Z-ligustilide potentiated dopamine toxicity in a dopaminergic cell specific manner. Using rat dopaminergic cell line PC12 as a model, we demonstrated that dopamine and Z-ligustilide in combination profoundly induced cell death, although these drugs alone, to a lesser extent, affected the cell viability in a concentration-dependent manner. The synergistic cytotoxicity of dopamine and Z-ligustilide is likely mediated via apoptosis, characterized by DNA fragmentation and chromatin shrinking after 12 h incubation. By measuring the intracellular reactive oxygen species (ROS) and reduced glutathione (GSH), Z-ligustilide and dopamine in combination dramatically enhanced the ROS formation and further depleted reduced GSH, whereas these drugs alone showed much less activity. Importantly, the synergistic cytotoxicity of dopamine and Z-ligustilide could be largely prevented by thiol-containing antioxidant N-acetylcysteine and GSH other than vitamin C and Trolox. Since the cytotoxicity of Z-ligustilide was not reported previously, the results of this study should raise public concerns over the potential risk associated with the combined use of herbal medicines containing Z-ligustilide with L-Dopa in the therapy of Parkinson's disease.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationNeurotoxicity Research, 2012, v. 22 n. 4, p. 345-354 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12640-012-9319-6
dc.identifier.doihttp://dx.doi.org/10.1007/s12640-012-9319-6
dc.identifier.epage354
dc.identifier.hkuros203763
dc.identifier.issn1029-8428
2011 Impact Factor: 3.514
2011 SCImago Journal Rankings: 0.230
dc.identifier.issue4
dc.identifier.pmid22451226
dc.identifier.scopuseid_2-s2.0-84870299180
dc.identifier.spage345
dc.identifier.urihttp://hdl.handle.net/10722/152802
dc.identifier.volume22
dc.languageeng
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springerlink.com/content/1029-8428
dc.publisher.placeUnited States
dc.relation.ispartofNeurotoxicity Research
dc.rightsThe original publication is available at www.springerlink.com
dc.subjectCytotoxicity
dc.subjectDopamine
dc.subjectParkinson's disease
dc.subjectReactive oxygen species
dc.subjectReduced glutathione
dc.titleZ-ligustilide potentiates the cytotoxicity of dopamine in rat dopaminergic PC12 cells
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine
  2. Hong Kong Polytechnic University